Mereo BioPharma Group PLC is a United Kingdom (U... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RW | 26.17 | 0.09 | +0.35% |
| Rainwater Equity ETF (RW) | |||
| HYGV | 38.54 | 0.07 | +0.19% |
| Northern Trust High Yield Value-Scored Bond ETF (HYGV) | |||
| PBTP | 25.60 | -0.01 | -0.04% |
| Invesco 0-5 Yr US TIPS ETF (PBTP) | |||
| RSEE | 37.00 | -0.11 | -0.30% |
| Rareview Systematic Equity ETF (RSEE) | |||
| ELC | 18.11 | -0.20 | -1.09% |
| Entergy Louisiana LLC | |||
A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.
| Ticker / NAME | Correlation To MREO | 1D Price Change % | ||
|---|---|---|---|---|
| MREO | 100% | +2.92% | ||
| RARE - MREO | 58% Loosely correlated | +3.47% | ||
| TRDA - MREO | 40% Loosely correlated | +3.62% | ||
| SYRE - MREO | 38% Loosely correlated | +2.24% | ||
| XNCR - MREO | 38% Loosely correlated | +1.47% | ||
| NRIX - MREO | 38% Loosely correlated | +2.83% | ||
More | ||||
a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease
Industry Biotechnology
MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 32 cases where MREO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where MREO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MREO as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for MREO just turned positive on November 09, 2026. Looking at past instances where MREO's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Following a +6.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
MREO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MREO crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MREO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (3.498). P/E Ratio (-1.415) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (102.041) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.